Whan In PharmLtd Past Earnings Performance
Past criteria checks 2/6
Whan In PharmLtd has been growing earnings at an average annual rate of 7.5%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 9.6% per year. Whan In PharmLtd's return on equity is 7.3%, and it has net margins of 10.9%.
Key information
7.5%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.6% |
| Return on equity | 7.3% |
| Net Margin | 10.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Did Whan In Pharm Co.,Ltd. (KRX:016580) Use Debt To Deliver Its ROE Of 7.8%?
Mar 15
Here's Why I Think Whan In PharmLtd (KRX:016580) Might Deserve Your Attention Today
Feb 25Whan In Pharm Co.,Ltd.'s (KRX:016580) 1.6% Dividend Yield Looks Pretty Interesting
Feb 04
What Is The Ownership Structure Like For Whan In Pharm Co.,Ltd. (KRX:016580)?
Jan 14Why You Might Be Interested In Whan In Pharm Co.,Ltd. (KRX:016580) For Its Upcoming Dividend
Dec 24Does Whan In Pharm Co.,Ltd. (KRX:016580) Create Value For Shareholders?
Dec 11Whan In PharmLtd's (KRX:016580) Shareholders Are Down 33% On Their Shares
Nov 20Revenue & Expenses Breakdown
How Whan In PharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 251,729 | 27,364 | 66,262 | 573 |
| 30 Jun 24 | 242,456 | 29,191 | 66,280 | 636 |
| 31 Mar 24 | 236,463 | 31,727 | 65,688 | 736 |
| 31 Dec 23 | 230,394 | 29,774 | 65,345 | 1,072 |
| 30 Sep 23 | 224,164 | 27,469 | 64,946 | 1,358 |
| 30 Jun 23 | 214,684 | 25,886 | 63,616 | 3,349 |
| 31 Mar 23 | 205,629 | 22,712 | 63,962 | 3,564 |
| 31 Dec 22 | 198,935 | 23,921 | 63,014 | 3,331 |
| 30 Sep 22 | 191,764 | 22,517 | 63,041 | 4,150 |
| 30 Jun 22 | 187,376 | 23,764 | 61,904 | 2,367 |
| 31 Mar 22 | 181,398 | 25,042 | 58,493 | 2,540 |
| 31 Dec 21 | 177,776 | 26,660 | 56,942 | 2,659 |
| 30 Sep 21 | 176,995 | 27,456 | 55,638 | 1,838 |
| 30 Jun 21 | 175,353 | 28,898 | 53,945 | 1,670 |
| 31 Mar 21 | 174,884 | 26,901 | 53,735 | 1,577 |
| 31 Dec 20 | 171,705 | 23,388 | 52,431 | 3,312 |
| 30 Sep 20 | 166,094 | 21,795 | 50,313 | 3,288 |
| 30 Jun 20 | 163,538 | 19,548 | 50,047 | 3,197 |
| 31 Mar 20 | 161,934 | 17,492 | 49,730 | 2,968 |
| 31 Dec 19 | 159,177 | 18,696 | 49,773 | 993 |
| 30 Sep 19 | 157,489 | 19,627 | 49,489 | 610 |
| 30 Jun 19 | 156,534 | 19,971 | 49,136 | 524 |
| 31 Mar 19 | 155,832 | 23,436 | 49,164 | 527 |
| 31 Dec 18 | 154,664 | 21,518 | 49,573 | 648 |
Quality Earnings: A016580 has high quality earnings.
Growing Profit Margin: A016580's current net profit margins (10.9%) are lower than last year (12.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A016580's earnings have grown by 7.5% per year over the past 5 years.
Accelerating Growth: A016580's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A016580 had negative earnings growth (-0.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22%).
Return on Equity
High ROE: A016580's Return on Equity (7.3%) is considered low.